Basilea.com : Basilea
We are committed to developing and commercializing innovative pharmaceutical products to meet the medical needs of patients with serious and life-threatening conditions. Basilea is located in the Basel area, Switzerland and listed on the SIX Swiss Exchange (SIX: BSLN).
What we do : Basilea
Anti-infectives, specifically antifungals and antibiotics, is the key focus of Basilea’s strategy. We have successfully brought two anti-infective drugs to the market: the antifungal Cresemba (isavuconazole) and the antibiotic Zevtera (ceftobiprole).
Who we are : Basilea
2024年8月30日 · Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland. Basilea has about 150 employees. We are committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with severe bacterial or fungal infections.
Investor center : Basilea
2024年10月22日 · At Basilea, we have performed a materiality analysis in 2023 that helped us to understand, which environmental, social, governance (ESG) and economic topics matter most in the context of Basilea’s business model. These material topics …
News : Basilea
2015年7月19日 · Basilea reports strong financial results for half-year 2021 with significantly increased cash flow from marketed brands and increases 2021 full-year guidance. Read more.
Careers : Basilea
Become part of Basilea. If you wish to become a part of a multinational, innovative team that strives to make a difference to patients’ outcomes worldwide, we would love to hear from you.
Contact : Basilea
Basilea Pharmaceutica International Ltd, Allschwil Hegenheimermattweg 167b 4123 Allschwil Switzerland. P: +41 61 606 11 11. E-mail: [email protected]
News - Basilea
2024年9月19日 · Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland. We are committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with severe bacterial and fungal infections.
News - Basilea
Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland. We are committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with cancer and infectious diseases.
News - Basilea
2023年1月11日 · In February 2022, Basilea announced the strategic decision to focus exclusively on anti-infectives going forwards and to exit oncology by the end of 2022. By November 2022, Basilea had entered into three separate transactions with innovative oncology companies.